Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Cash from Investing Activities (2020 - 2025)

Quantum Biopharma's Cash from Investing Activities history spans 5 years, with the latest figure at $350650.0 for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 71.81% to $350650.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $222167.0, a 98.29% decrease, with the full-year FY2025 number at -$2.0 million, down 29.86% from a year prior.
  • Cash from Investing Activities hit $350650.0 in Q4 2025 for Quantum Biopharma, up from -$1.4 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for QNTM hit a ceiling of $11.9 million in Q4 2022 and a floor of -$1.4 million in Q1 2025.
  • Historically, Cash from Investing Activities has averaged $1.8 million across 4 years, with a median of $350650.0 in 2025.
  • The widest YoY moves for Cash from Investing Activities: up 71.81% in 2025, down 5998.5% in 2025.
  • Tracing QNTM's Cash from Investing Activities over 4 years: stood at $500000.0 in 2021, then surged by 2281.68% to $11.9 million in 2022, then plummeted by 89.55% to $1.2 million in 2024, then crashed by 71.81% to $350650.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for QNTM at $350650.0 in Q4 2025, -$1.4 million in Q1 2025, and $1.2 million in Q4 2024.